Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA.
Antimicrob Agents Chemother. 2010 Feb;54(2):742-8. doi: 10.1128/AAC.00621-09. Epub 2009 Nov 23.
Since the year 2000, linezolid has been used in the United States to treat infections caused by antimicrobial-resistant Gram-positive cocci. At present, linezolid-resistant (Linr) Staphylococcus aureus and Staphylococcus epidermidis strains are rare and the diversity of their genetic backgrounds is unknown. We performed sequence-based strain typing and resistance gene characterization of 46 Linr isolates that were collected from local and national sources between the years 2004 and 2007. Resistance was found to occur in at least three clonal complexes (CCs; lineages) of S. aureus and in at least four subclusters of a predominant, phylogenetically unstable CC of S. epidermidis. New candidate resistance mutations in 23S rRNA and the L4 riboprotein were identified among the S. epidermidis isolates. These findings suggest that linezolid resistance has emerged independently in multiple clones of S. aureus and with a variety of ribosomal mutations in multiple clones of S. epidermidis.
自 2000 年以来,利奈唑胺已被用于美国治疗由耐抗菌药物的革兰阳性球菌引起的感染。目前,耐利奈唑胺(Linr)的金黄色葡萄球菌和表皮葡萄球菌菌株较为罕见,其遗传背景的多样性尚不清楚。我们对 2004 年至 2007 年间从本地和全国来源收集的 46 株 Linr 分离株进行了基于序列的菌株分型和耐药基因特征分析。结果发现,金黄色葡萄球菌至少有三个克隆复合体(CC;谱系)和表皮葡萄球菌中一个主要的、进化不稳定的 CC 的至少四个亚群存在耐药性。在表皮葡萄球菌分离株中还发现了 23S rRNA 和 L4 核糖体蛋白中的新候选耐药突变。这些发现表明,利奈唑胺耐药性已在金黄色葡萄球菌的多个克隆中独立出现,并在表皮葡萄球菌的多个克隆中存在多种核糖体突变。